Loading clinical trials...

A Study of Safety and Efficacy in MK-0954A Combination in Participants With Hypertension (MK-0954A-373 AM3) | Clinical Trials | Clareo Health

COMPLETEDPHASE4

A Study of Safety and Efficacy in MK-0954A Combination in Participants With Hypertension (MK-0954A-373 AM3)

An Open-label, Single Arm, Prospective Study to Evaluate the Safety and Anti-hypertensive Efficacy of Losartan 50 mg / Hydrochlorothiazide (HCTZ) 12.5 mg Combination in Patients With Mild to Moderate Essential Hypertension

NCT01431508•Organon and Co

View on ClinicalTrials.gov

Summary

This study is being conducted to evaluate the safety and antihypertensive efficacy of MK-0954A (Losartan 50 mg / Hydrochlorothiazide (HCTZ) 12.5 mg) in participants with mild to moderate essential hypertension.

Eligibility

Age

20 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Participant will have reached the legal age by the time of entrance into the run-in period.
•Participant has no active medical problem, other than essential hypertension,
•which might of itself or by this treatment significantly affect the Participant's blood pressure.
•\- Participants diagnosed with mild to moderate essential hypertension or
•hypertension accompanying with established cardiovascular (CV) and renal diseases who are receiving antihypertensive regimen (exclude diuretic), yet not attaining to treatment goal\*.
•\* Note: For essential hypertension, the goal is to reduce the blood pressure to less than 140/90. For hypertension with established CV and renal diseases, the BP goal is \< 130/80. (According to 2007 European Society of Hypertension (ESH) - European Society of Cardiology (ESC) guideline)
•Participant is either receiving antihypertensive therapy or no treatment.
•Participants with stable diabetes mellitus may enter the study.

Exclusion Criteria

•Pregnant or lactating females.
•Secondary hypertension of any etiology (such as unilateral or bilateral renal
•disease, renal artery stenosis, coarctation of the aorta, pheochromocytoma).
•History of malignant hypertension.
•Sitting systolic blood pressure \>210 mmHg at Visit 1 (Day 0).
•Participants with unresolved cerebrovascular accident or transient ischemic attack in the acute stage at visit 1.
•A clinically confirmed myocardial infarction within the recent 3 months.
•Angina pectoris.
•Clinically important cardiac arrhythmia.
•History of unexplained syncope within the prior 2 years, or a known syncopal
+5 more criteria

Key Dates

Start Date

August 1, 2007

Primary Completion Date

June 1, 2009

Completion Date

June 1, 2009

Last Updated

May 22, 2024

Enrollment

ACTUAL participants

Conditions

Hypertension

Interventions

Losartan 50 mg / HCTZ 12.5 mg

DRUG

Natural History of Noncirrhotic Portal Hypertension

NCT02417740

Cystic FibrosisImmunologic Deficiency Syndrome+3 more

View study

RECRUITINGPHASE2

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

NCT07073820

Pulmonary Hypertension

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 22, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of Safety and Efficacy in MK-0954A Combination in Participants With Hypertension (MK-0954A-373 AM3)

Inclusion Criteria

Exclusion Criteria

Natural History of Noncirrhotic Portal Hypertension

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

Homocysteine and Early Diastolic Dysfunction in Newly Diagnosed Hypertension

Mobile Cued Adherence Therapy (mCAT) for Blood Pressure Medication

Penn Medicine Healthy Heart

Preliminary Human Trials of F230 Tablets